載入...
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been recently approved as an add-on biological treatment for severe eosinophilic asthma, by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Moreover, mepolizumab is also current...
Na minha lista:
| 發表在: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5669784/ https://ncbi.nlm.nih.gov/pubmed/29133975 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S150656 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|